Lb Pharmaceuticals (LBRX) Accumulated Expenses (2024 - 2026)

Lb Pharmaceuticals' Accumulated Expenses history runs 3 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Accumulated Expenses changed N/A year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (changed N/A YoY), while the FY2025 annual figure was $1.7 million, up 16.59% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.1 million, down from $1.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $3.3 million in Q3 2025, with the low at $1.1 million in Q1 2026.
• The 3-year median for Accumulated Expenses is $1.6 million (2024), against an average of $1.9 million.
• Peak annual rise in Accumulated Expenses reached 16.59% in 2025, while the deepest fall reached 16.59% in 2025.
• Lb Pharmaceuticals' Accumulated Expenses stood at $1.4 million in 2024, then climbed by 16.59% to $1.7 million in 2025, then sank by 35.12% to $1.1 million in 2026.
• Business Quant data shows LBRX's Accumulated Expenses at $1.1 million in Q1 2026, $1.7 million in Q4 2025, and $3.3 million in Q3 2025.